Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Descriptive summary of specialty of prescribing physician
Timeframe: Retrospective data analysis from 2022 to 2024
Date of finerenone initiation
Timeframe: Retrospective data analysis from 2022 to 2024
If patient was receiving finerenone at the time of each follow-up visit (Yes/No)
Timeframe: Retrospective data analysis from 2022 to 2024
Date of discontinuation of finerenone
Timeframe: Retrospective data analysis from 2022 to 2024
Reason for discontinuation of finerenone
Timeframe: Retrospective data analysis from 2022 to 2024
Dose of finerenone treatment
Timeframe: Retrospective data analysis from 2022 to 2024
Frequency of finerenone treatment
Timeframe: Retrospective data analysis from 2022 to 2024
The number of patients who initiated finerenone with a 10-mg dose and 20-mg dose
Timeframe: Retrospective data analysis from 2022 to 2024
The proportion of patients who initiated finerenone with a 10-mg dose and have up-titrated to a 20-mg dose
Timeframe: Retrospective data analysis from 2022 to 2024
The proportion of patients who initiated finerenone with a 20-mg dose and have down-titrated to a 10-mg dose
Timeframe: Retrospective data analysis from 2022 to 2024
Actions taken after finerenone introduction
Timeframe: Retrospective data analysis from 2022 to 2024
Actions taken after stop finerenone prescription
Timeframe: Retrospective data analysis from 2022 to 2024